Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy
- 1 September 2002
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (17) , 3703-3718
- https://doi.org/10.1200/jco.2002.03.052
Abstract
PURPOSE: To explain the variability of docetaxel pharmacokinetics through study of CYP3A phenotype and genotype, and MDR1 genotype.Keywords
This publication has 95 references indexed in Scilit:
- Cognitive Function and Reproductive Hormones in Adjuvant Therapy for Breast CancerJournal of Pain and Symptom Management, 2001
- Paroxetine for the Prevention of Depression Induced by High-Dose Interferon AlfaNew England Journal of Medicine, 2001
- Managing Cancer-Related Anorexia/CachexiaDrugs, 2001
- Regulation of the hypothalamo–pituitary–adrenal axis by cytokinesBest Practice & Research Clinical Endocrinology & Metabolism, 1999
- Rural surgery, caring for developing communitiesBritish Journal of Surgery, 1999
- Adjuvant IFNα2 therapy of melanomaThe Lancet, 1998
- Hypertriglyceridemia may be severe in CML patients treated with interferon‐αAmerican Journal of Hematology, 1995
- Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alphaClinical and Experimental Immunology, 1992
- Serum sex steroid and peptide hormone concentrations, and endometrial estrogen and progestin receptor levels during administration of human leukocyte interferonInternational Journal of Cancer, 1982
- Common pathways of interferon and hormonal actionNature, 1980